Also, the pan-PI3K inhibitor PX-866 did not improve PFS, overall response rate (ORR), or OS in pretreated R/M HNSCC when combined with docetaxel or cetuximab (10, 11). Here, PIK3CA is linked to head and neck squamous cell carcinoma.